StockMacro
Menu

Vogenx

$11.87 -8.7% in 6 monthsMarket cap $176.3M

VOGX on XNAS, Health Care, Vogenx Inc, job postings

Measures activity, not value. Not investment advice.

Shares fell 42% in one month while two director or officer changes were filed in 90 days.

  • WatchCash of $82.1M stands against a $176.3M market value

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.

Industry
Pharmaceutical preparations (Health Care)
Employees
7
Website
vogenx.com
Listed
Nasdaq, US
Last results
6 Nov 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $4.9M.
Quarter to 31 Mar 2025: revenue –, net income -$357KQuarter to 30 Jun 2025: revenue –, net income -$295KQuarter to 30 Sep 2025: revenue –, net income -$284KQuarter to 31 Mar 2026: revenue –, net income -$475KQuarter to 30 Jun 2026: revenue –, net income -$384KQuarter to 30 Sep 2026: revenue –, net income -$4.9M
31 Mar 2025RevenueNet incomeNet losstallest bar $4.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$4.9M
30 Jun 2026–-$384K
31 Mar 2026–-$475K
30 Sep 2025–-$284K
30 Jun 2025–-$295K
31 Mar 2025–-$357K
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. – –
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $82.1M $234K
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $5.52
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. – 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.2 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
VogenxVOGX (this company) $176.3M––––
Nature's Sunshine ProductsNATR $176.4M12.00.37+1.2%3.1%
ADC Therapeutics SAADCT $180.0Mloss1.9+13%-95.7%
SIGA TechnologiesSIGA $172.5M2513.3-70%1.3%
Whitehawk TherapeuticsWHWK $181.2Mloss–––
Entrada TherapeuticsTRDA $170.3Mloss42.8-94%–

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

53%

7.9M shares held by 13F filers (30 Sep 2026) of 14.9M outstanding (5 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.5%

74K shares sold short (30 Oct 2026) of 14.9M outstanding (5 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

74K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+94%

38K shares sold short in the report before, 74K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

23%

23% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

12

12 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

12 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $11.87 on 20 Nov 2026, -8.7% over 12 months (12-month range $11.87 to $34.13)

  • Sharp change
  • 8-K and other filings
Institutional holders (13F filers). 30 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: insider net buying (open market), h-1b/e-3 applications certified, revenue per quarter, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
9 Oct 20268-K and other filingsDirector or officer change
22 Sep 20268-K and other filingsDirector or officer change
22 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Aug 20268-K and other filingsRegistered new securities for sale (S-1)
29 Jul 20268-K and other filingsRegistered new securities for sale (S-1)
15 Jul 20268-K and other filingsRegistered new securities for sale (S-1)
7 Jan 20268-K and other filingsPrivate placement of securities (Form D)
Institutional holders (13F filers)
30 Sep 2026 report: 30; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is short-term investments at period end at $77.0M (30 Sep 2026), too little history to compare.
  • Institutional holders (13F filers): 30 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

30 institutions reported shares at the end of Q3 2026, 53% of the shares outstanding; 29 opened a position, 0 sold out. From 13F reports.

InstitutionShares% of companyValueChange
Janus Henderson Group Ltd.1.9M12.9%$44.7M
Orbimed Advisors LLC969K6.52%$22.1M
Affinity Asset Advisors, LLC915K6.16%$20.9M
Adage Capital Partners GP, L.L.C.800K5.39%$18.2M
Deerfield Management Company, L.P.636K4.28%$14.5M
Longbow Finance SA600K4.04%$13.7M
ADAR1 Capital Management, LLC522K3.52%$11.9M
AWM Investment Company, Inc.259K1.74%$5.9M
Acuta Capital Partners, LLC213K1.44%$4.9M
Ikarian Capital, LLC209K1.41%$4.8M

Company events

All 6 company events

In 12 months: 3 share registrations, 2 director or officer changes, 1 private placement. Results releases and routine reports are left out.

FiledWhat happenedSource
9 Oct 2026Director or officer change8-K
22 Sep 2026Director or officer change8-K
10 Aug 2026Registered new securities for sale (S-1)S-1/A
29 Jul 2026Registered new securities for sale (S-1)S-1/A
15 Jul 2026Registered new securities for sale (S-1)S-1
6 Jan 2026Private placement of securities (Form D)$750K sold of $5.0M offeredD

The 5 newest of 44 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 9 Oct 2026Filings record

    Director or officer change

  2. 22 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 22 Sep 2026Filings record

    Director or officer change

  4. 10 Aug 2026Filings record

    Registered new securities for sale (S-1)

  5. 29 Jul 2026Filings record

    Registered new securities for sale (S-1)

  6. 15 Jul 2026Filings record

    Registered new securities for sale (S-1)

  7. 7 Jan 2026Filings record

    Private placement of securities (Form D) (dated 6 Jan 2026)

Not listed: 4 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001903784
Ticker
VOGX
Domain
vogenx.com
Hq location
NC|RALEIGH|27609 (1 unverified)
Name
Vogenx Inc
  • SEC Form 13F institutional holdings9 data points30 Sep 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)10 records6 Jan 2026 to 6 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)44 data points31 Dec 2024 to 5 Nov 2026
  • FINRA short interest (twice monthly)17 data points14 Aug 2026 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)144 data points12 Aug 2026 to 20 Nov 2026